Abstracts tagged "Cancer"

Abstract Number: 0422 • ACR Convergence 2021
Cancer in Patients with ANCA-associated Vasculitis: Which Came First, the Chicken or the Egg?
Elif Ediboglu¹, Riza Can Kardas², Ertugrul Cagri bolek³, Resit Yildirim⁴, DenizCan Guven⁵, Saadettin Kilickap⁵, Omer Dizdar⁵, Melek Yalcin Mutlu⁶, Ozan Cemal Icacan⁷, Gizem Ayan⁸, Emre Bilgin⁸, Nazife Sule Yasar Bilge⁹, Levent Kilic⁸, Timucin Kasifoglu⁴, Cemal Bes¹⁰, Servet Akar¹¹ and Omer Karadag¹², ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ³Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁴Eskisehir Osmangazi University, Department of Internal Medicine, Division of Rheumatology, Eskisehir, Turkey, ⁵Hacettepe University Medical Faculty, Department of Medical Oncology, Ankara, Turkey, ⁶University of Health Sciences, Istanbul, ⁷University of Health Sciences, Istanbul, Turkey, ⁸Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁹Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey, ¹⁰Saglik Bilimleri University, Basaksehir Cam and Sakura State Hospital – Istanbul, Turkey, Istanbul, Turkey, ¹¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ¹²Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey
Background/Purpose: Many studies linking vasculitis to the development of malignancy based on chronic inflammation, cytotoxicity, emergence of vasculitis as a paraneoplastic disease. Even previous studies…
Abstract Number: 0688 • ACR Convergence 2021
Standardized Prevalence Ratios of Cancer in Idiopathic Inflammatory Myositis
Christopher Mecoli¹, Takeru Igusa², Mengkun Chen³, XingYao Wang², Jemima Albayda², Julie Paik², Eleni Tiniakou², Brittany Adler², Carrie Richardson⁴, William Kelly², Sonye Danoff⁵, Andrew Mammen⁶, Elizabeth Platz³, Antony Rosen², Lisa Christopher-Stine², Livia Casciola-Rosen⁷ and Ami Shah⁸, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Johns Hopkins University, Baltimore, MD, ³Johns Hopkins School of Public Health, Baltimore, MD, ⁴Rush University Medical Center, Chicago, IL, ⁵Johns Hopkins Medicine, Baltimore, MD, ⁶National Institutes of Health, Bethesda, MD, ⁷Johns Hopkins, Baltimore, MD, ⁸Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: Whether the likelihood of a cancer diagnosis in idiopathic inflammatory myopathy (IIM) patients differs by autoantibody type is not fully characterized. To inform cancer…
Abstract Number: 0701 • ACR Convergence 2021
Use and Yield of Computed Tomography as a Cancer Surveillance Method in Idiopathic Inflammatory Myositis
Christopher Mecoli¹, Brant Chee², XingYao Wang³, Mengkun Chen⁴, William Kelly³, Elizabeth Platz⁴, Livia Casciola-Rosen⁵, Lisa Christopher-Stine³ and Ami Shah⁶, ¹Johns Hopkins University School of Medicine, Baltimore, MD, ²Applied Physics Laboratory, Baltimore, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins School of Public Health, Baltimore, MD, ⁵Johns Hopkins, Baltimore, MD, ⁶Johns Hopkins Rheumatology, Baltimore, MD
Background/Purpose: To inform guidance for cancer surveillance in patients with idiopathic inflammatory myositis (IIM), we conducted a retrospective cohort study in a single tertiary referral…
Abstract Number: 1041 • ACR Convergence 2021
Do Cancer Risks Increased in the Five Major Autoimmune Diseases? A Large Cohort Study in China
Huazhen Liu¹, Ziyue Zhou¹, Yangzhong Zhou¹, Jingya Zhou¹, Yiying Yang¹, Zhuoran Yao¹, Xiaoxiang Zhou¹, Wen Zhang¹, Yan Zhao¹, Mengtao Li¹, Xiaofeng Zeng¹, Fengchun Zhang², Huaxia Yang¹ and Xuan Zhang¹, ¹Peking Union Medical College Hospital, Beijing, China (People's Republic), ²Peking Union Medical College Hospital, Internal Medicine Department, Beijing, China (People's Republic)
Background/Purpose: Cancer is a comorbidity of concern for the long-term prognosis in autoimmune disease (AID) patients. This study investigated cancer incidence and risks in five…
Abstract Number: 1098 • ACR Convergence 2021
Does Cancer Masquerade as Sarcoidosis?
Daniel Albert, Dartmouth-Hitchcock, Etna, NH
Background/Purpose: Several case reports have suggested that cancer can present occultly as a granulomatous inflammatory disease consistent with sarcoidosis. These cases illustrate a problem of…
Abstract Number: 1467 • ACR Convergence 2021
Determinants of Cervical Cancer Screening Patterns Among Women with Systemic Lupus Erythematosus
Sarah Chung¹, Kimiko Oshima¹, Jenna Thomason¹, Michael Singleton¹ and Namrata Singh², ¹University of Washington, Seattle, WA, ²University of Washington, Bellevue, WA
Background/Purpose: Women with systemic lupus erythematosus (SLE) are vulnerable to cervical dysplasia. This is due to the persistence of human papillomavirus (HPV) related to immunosuppression…
Abstract Number: 0133 • ACR Convergence 2021
Cervical Cancer Screening Rate in Women with Systemic Lupus Erythematosus
Erica Rosen¹ and Megan Krause², ¹University of Kansas, Kansas City, MO, ²University of Kansas, Kansas City, KS
Background/Purpose: Females with systemic lupus erythematosus have increased rates of cervical cancer especially if on immunosuppressive therapy. The American Cancer Society reports the incidence of…
Abstract Number: 010 • 2020 Pediatric Rheumatology Symposium
Experience with and Management of HLH-like Toxicities Following Chimeric Antigen Receptor T-Cell Therapy for Treatment of Relapsed/Refractory Pre-B ALL
Amanda Ombrello¹, Bonnie Yates ², Haneen Shalabi ², Terry Fry ³ and Nirali Shah ², ¹National Human Genome Research Institute/National Institutes of Health, Bethesda, ²National Cancer Institute/National Institutes of Health, Bethesda, ³University of Colorado, Denver/Children's Hospital Colorado, Denver
Background/Purpose: Chimeric antigen receptor T-cell (CAR-T) therapy is a highly effective form of adoptive cell immunotherapy combining antigen specific targeting capabilities with T-cell based cytotoxicity.…
Abstract Number: 397 • 2019 ACR/ARP Annual Meeting
Clinical Features of Polymyositis and Dermatomyositis Patients with Severe Dysphagia
Nozomi Takasugi¹, Yutaro Hayashi ¹, Keisuke Izumi ², Satoshi Hama ³, Misako Konishi ¹, Mari Ushikubo ¹, Yutaka Okano ¹ and Hisaji Ohshima ¹, ¹National Tokyo Medical Center, tokyo, Japan, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³tokyo medical center, tokyo, Japan
Background/Purpose: Polymyositis (PM) and dermatomyositis (DM) are autoimmune inflammatory diseases characterized by proximal myositis. Dysphagia has been reported to develop in 35 to 62% of…
Abstract Number: 410 • 2019 ACR/ARP Annual Meeting
Prevalence of Malignancy in Myositis Patients with Anti-aminoacyl-tRNA Synthetase Antibodies: A Single Center Retrospective Study and Literature Review
Taiga Kuga¹, Yoshiyuki Abe ², Kurisu Tada ³, Masakazu Matsushita ¹, Ken Yamaji ¹ and Naoto Tamura ¹, ¹Department of Internal Medicine and Rheumatology, Juntendo University School of Medicine, Tokyo, Japan, ²Department of Rheumatology, Juntendo University, Tokyo, Japan, Tokyo, Japan, ³Juntendo University School of Medicine, Tokyo, Japan
Background/Purpose: Anti-aminoacyl-tRNA synthetase antibodies (anti-ARS antibodies) are related to Idiopathic Inflammatory Myopathy (IIM) and Anti-Synthetase Syndrome (ASS). While anti-TIF1-γ antibody and anti-NXP-2 antibody are highly…
Abstract Number: 1199 • 2019 ACR/ARP Annual Meeting
Improving Rates of Cervical Cancer Screening and HPV Vaccination in Patients with Lupus
Nancy Desai¹, Hanni Menn-Josephy ¹, Ramon Bonegio ¹, Christina Lam ¹, Anna Kancharla ¹ and Michael York ¹, ¹Boston Medical Center, Boston
Background/Purpose: Patients with lupus have higher rates of cervical dysplasia and pre-malignant cervical lesions. At our institution, an urban referral center for patients with lupus, rates…
Abstract Number: 1811 • 2019 ACR/ARP Annual Meeting
Commonly Used Drugs in Rheumatology May Alter Anti-Tumoral Response to Immune Checkpoint Inhibitors
Marie Kostine¹, Eleonora Mauric ², Thomas Barnetche ³, Léa Rouxel ³, Caroline Dutriaux ⁴, Léa Dousset ⁴, Sorilla Prey ⁴, Marie Beylot-Barry ⁴, Julien Seneschal ⁵, Rémi Veillon ⁶, Vergnenegre Charlotte ⁶, Amaury Daste ⁷, Domblides Charlotte ⁷, Baptiste Sionneau ⁷, Marine Gross-Goupil ⁷, Alain Ravaud ⁷, Edouard Forcade ⁸, Bernard Bannwarth ³, Nadia Mehsen-Cetre ³, Marie-Elise Truchetet ⁹, Christophe Richez ¹⁰ and Thierry Schaeverbeke ³, ¹Department of Rheumatology, Bordeaux, France, ²FHU ACRONIM, Bordeaux University Hospital, Bordeaux, France, ³FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ⁴FHU ACRONIM, Department of Dermatology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ⁵department of dermatology, centre hospitalier universitaire de Bordeaux, BORDEAUX, France, ⁶Department of Pneumology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ⁷Department of Oncology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ⁸Department of Hematology, Centre Hospitalier Universitaire, Bordeaux, France, Bordeaux, France, ⁹FHU ACRONIM, Department of Rheumatology, Centre Hospitalier Universitaire, Bordeaux, France. Bordeaux University, CNRS 5164, 33000 Bordeaux, France, Bordeaux, France, ¹⁰Pellegrin Hospital, University Hospital of Bordeaux, Bordeaux, France
Background/Purpose: Immune checkpoint inhibitors (ICIs) are revolutionizing the treatment of some advanced cancers. Gut microbiota has emerged as an important component of anti-tumoral response and…
Abstract Number: 1903 • 2019 ACR/ARP Annual Meeting
BTK Overexpression Is Associated with the Risk of Lymphoma in Primary Sjögren’s Syndrome: Data from Whole Blood Transcriptome of 346 Patients Followed-up Prospectively for 10 Years
Pierre-Marie Duret¹, Tao Ye ², Wan-Fai Ng ³, Alain Saraux ⁴, Valérie Devauchelle Pensec ⁵, Raphaele Seror ⁶, Veronique Le-Guern ⁷, Claire Larroche ⁸, Aleth Perdriger ⁹, Jean Sibilia ¹⁰, Jessica Tarn ¹¹, Gaetane Nocturne ¹², Xavier Mariette ¹³ and Jacques-Eric Gottenberg ¹⁴, ¹Hôpitaux civils de Colmar, COLMAR CEDEX, France, ²GenomEAST platform / Institut National de la Santé et de la Recherche Médicale (INSERM), U1258, Institut de Génétique et de Biologie Moléculaire, IGBMC, Strasbourg, France, ³Musculoskeletal Research Group Institute of Cellular Medicine Faculty of Medical Sciences Newcastle University, Newcastle, United Kingdom, ⁴CHU de la Cavale-Blanche Brest, Brest, France, ⁵University Hospital of Brest, Brest, France, ⁶Hopitaux universitaires Paris Sud, Kremlin-Bicetre, France, ⁷Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Paris, France,, Paris, France, ⁸Internal Medicine, Paris, France, Paris, France, ⁹Rheumatology department, Rennes University Hospital, France, Rennes, France, ¹⁰CHU Strasbourg, Strasbourg, France, ¹¹Institute of Cellular Medicine Newcastle University, Newcastle, United Kingdom, ¹²Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France., Paris, France, ¹³Center for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique – Hôpitaux de Paris, Hôpitaux Universitaires Paris-Sud, Le Kremlin-Bicêtre, Université Paris Sud, INSERM, Paris, France, ¹⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France
Background/Purpose: To identify a molecular signature associated with lymphomagenesis in primary Sjögren’s Syndrome (pSS).Methods: Whole peripheral blood samples were collected from 346 well-phenotyped pSS patients…
Abstract Number: 2158 • 2019 ACR/ARP Annual Meeting
Rheumatic Immune Related Adverse Events Associated with Cancer Immunotherapy: A Nationwide Multi-centre Canadian Cohort from the Canadian Research Group of Rheumatology in Immuno-oncology (CanRIO)
Janet Roberts¹, Daniel Ennis ², Marie Hudson ³, Carrie Ye ⁴, Alexandra Saltman ⁵, Sabrina Hoa ⁶, Janet Pope ⁷, Megan Himmel ², Nancy Maltez ⁸, Aurore Fifi-Mah ⁹, Annaliese Tisseverasinghe ¹⁰, Robert Rottapel ¹¹, Karam Al Jumaily ¹², Christina Ly ¹³, Liliana Cartagena ¹⁴ and Shahin Jamal ¹⁵, ¹Dalhousie University, Halifax, NS, Canada, ²University of Toronto, Toronto, ON, Canada, ³Jewish General Hospital, Lady Davis Institute for Medical Research, and Department of Medicine, McGill University, Montreal, QC, Canada, ⁴University of Alberta, Edmonton, AB, Canada, ⁵University of Toronto, Mount Sinai Hospital and Princess Margaret Cancer Centre, Toronto, ON, Canada, ⁶University of Montreal, Montreal, QC, Canada, ⁷Western University, London, ON, Canada, ⁸University of Ottawa, Ottawa, ON, Canada, ⁹University of Calgary, Calgary, AB, Canada, ¹⁰University of Manitoba, Winnipeg, MB, Canada, ¹¹University of Toronto, Toronto, Canada, ¹²University of Alberta, edmonton, Canada, ¹³McGill University, Montreal, Canada, ¹⁴Arthritis Research Canada, Vancouver, Canada, ¹⁵University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Immune checkpoint inhibitors (ICI) have revolutionized cancer therapy by harnessing the immune system to fight cancer. They are associated with the development of autoimmune…
Abstract Number: 2785 • 2019 ACR/ARP Annual Meeting
Cancer Risk in a Large Inception SLE Cohort: Effects of Age, Smoking, and Medications
Sasha Bernatsky¹, Rosalind Ramsey-Goldman ², Murray Urowitz ³, John Hanly ⁴, Caroline Gordon ⁵, Michelle Petri ⁶, Ellen M Ginzler ⁷, Daniel J Wallace ⁸, Sang-Cheol Bae ⁹, Juanita Romero-Diaz ¹⁰, MA Dooley ¹¹, Christine Peschken ¹², David A Isenberg ¹³, Anisur Rahman ¹⁴, Susan Manzi ¹⁵, Soren Jacobsen ¹⁶, S Sam Lim ¹⁷, Ronald F Van Vollenhoven ¹⁸, Ola Nived ¹⁹, Diane Kamen ²⁰, Cynthia Aranow ²¹, Jill Buyon ²², Guillermo Ruiz-Irastorza ²³, Ian Bruce ²⁴, Dafna Gladman ²⁵, Paul Fortin ²⁶, Joan T. Merrill ²⁷, Jorge Sanchez-Guerrero ²⁸, Kenneth C Kalunian ²⁹, Kristjan Steinsson ³⁰, Manuel Ramos ³¹, Asad Zoma ³², Thomas Stoll ³³, Munther A Khamashta ³⁴, Murat Inanc ³⁵ and Ann E Clarke ³⁶, ¹Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ²Northwestern University, Chicago, IL, ³University Health Network, University of Toronto, Toronto, ON, Canada, ⁴Queen Elizabeth II Health Science Centre (Nova Scotia Rehab Site), Halifax, NS, Canada, ⁵University of Birmingham, Birmingham, United Kingdom, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷State University of New York Downstate Medical Center, Brooklyn, NY, ⁸Cedars-Sinai Medical Centre, Beverly Hills, CA, ⁹Hanyang University Hospital for Rheumatic Diseases, Seoul, Republic of Korea, ¹⁰Instituto Nacional de Ciencias Medicas y Nutricion Salvador, Zubiran Vasco de Quiroga, Mexico City, Mexico, ¹¹UnC Kidney Centre, Chapel Hill, NC, ¹²University of Manitoba, Winnipeg, Canada, ¹³Centre for Rheumatology, London, United Kingdom, ¹⁴University College London, London, United Kingdom, ¹⁵Allegheny Health Network, Pittsburg, PA, ¹⁶Copenhagen Lupus and Vasculitis Clinic, Copenhagen, Denmark, ¹⁷Emory University, Atlanta, GA, ¹⁸Amsterdam Rheumatology & Immunology Center, Amsterdam, Netherlands, ¹⁹Lund University, Lund, Sweden, ²⁰Division of Rheumatology and Immunology, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA., Charleston, SC, ²¹Feinstein Institute for Medical Research, Manhasset, NY, ²²NYU School of Medicine, New York, ²³Autoimmune Diseases Unit, Hospital Universitario Cruces, Barakaldo, Spain, Barakaldo, Spain, ²⁴University of Manchester, Manchester, United Kingdom, Manchester, England, United Kingdom, ²⁵Toronto Western Hospital, Toronto, Canada, Toronto, ON, Canada, ²⁶Division de Rhumatologie, Département de Médecine, CHU de Québec – Université Laval, Axe maladies infectieuses et inflammatoires, Centre de recherche du CHU de Québec – Université Laval, Canada, Quebec, QC, Canada, ²⁷Okalahoma Medical Research Foundation, Oklahoma City, OK, ²⁸Toronto Western Hospital, Toronto, ON, Canada, ²⁹UC San Diego School of Medicine, LaJolla, CA, ³⁰Landspitali, University Hospital, Reykjavik, Iceland, ³¹Department of Internal Medicine, Hospital Nuestra Señora del Prado, Talavera, Talavera, Spain, Talavera, Spain, ³²Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, Scotland, United Kingdom, ³³University of Glasgow, Kilbride, Scotland, United Kingdom, ³⁴King's College London School of Medicine, London, United Kingdom, ³⁵Istanbul University, Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ³⁶University of Calgary, Calgary, AB, Canada
Background/Purpose: Many studies of cancer risk in SLE are limited by small sample size or use of administrative data, which rely on billing code diagnoses…

1
2
3
…
5
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].